



### Company Overview

BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the \$4 billion electrophysiology (EP) marketplace.

### BioSig Allowed First Key US Patent Claims for its PURE EP™ System

May 23 2019, 7:52 AM EDT

### Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors

May 21 2019, 7:52 AM EDT

### BioSig Technologies Completes Patient Cases at Indiana University

May 6 2019, 7:52 AM EDT

### Stock Overview

Symbol	BSGM
Exchange	Nasdaq
Market Cap	140.12m
Last Price	\$6.87
52-Week Range	\$3.50 - \$9.97
05/24/2019 04:00 PM EDT	

### Investor Relations

T: (866) 976-4784  
[ir@biosigtech.com](mailto:ir@biosigtech.com)

### Management Team

#### Kenneth L. Londoner, MBA

Founder, Chief Executive Officer, Chairman, and Director

#### Steve Chaussy

Chief Financial Officer

#### Natasha Drapeau

Executive Vice President

#### Dr. Barry Keenan, Ph.D., MBA, PMP

Vice President, Engineering

#### John Kowalski

Vice President, Sales

#### Amy Scott

Vice President, Strategic Partnerships

#### Tiffini Wittwer

FDA and Regulatory Advisor

#### Lora Mikolaitis

Vice President, Administration

### BioSig Technologies, Inc.

12424 Wilshire Blvd  
Suite 745  
Los Angeles, CA 90025

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.